Ucb S.a. · EURONEXT:UCB
Ucb — Technical Presentation (May 2022)
59 slides from Ucb's technical presentation, May 2022
Slide 1: UCB Virtual Briefing: Bimekizumab Phase 3 Studies in axSpA and PsA
UCB VIRTUAL BRIEFING: Bimekizumab Phase 3 Studies in Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis (PsA) © UCB Biopharma SRL, 2022. All rights reserved Bimekizumab is not approved for use in nr-axSpA, AS or PsA by any regulatory authority worldwide. Date of preparation: May 2022. GL-N-BK-A
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking st
Slide 3: Agenda
01 Welcome Antje Witte, Head of Investor Relations, UCB 02 Introduction Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of US, UCB 03 Background Bimekizumab Phase 3 Studies in Proprietary and Confidential Property of UCB Axial Spondyloarthritis and Psoriatic Arthritis Dr.
Slide 4: Welcome
Proprietary and Confidential Property of UCB Emmanuel Caeymaex Welcome Executive Vice President Immunology Solutions and Head of US, UCB GL-N-BK-AS-2200005 Date of preparation: May 2022 4
Slide 5: BIMZELX first IL-17A and IL-17F inhibitor approved for plaque psoriasis
BIMZELX®▼(bimekizumab) is the first IL-17A and IL-17F inhibitor approved for the treatment of moderate to severe plaque psoriasis European Union August 20211 Proprietary and Confidential Property of UCB Great Britain August 20212 Japan January 20223 Canada February 20224 Australia March 20225 Pre-fi
Slide 6: BE RADIANT: bimekizumab vs secukinumab in psoriasis, PASI 100 through 96 weeks
In psoriasis, the Phase 3 BE RADIANT study showed that inhibition of IL-17A and IL-17F with bimekizumab was superior to inhibition of IL-17A with secukinumab with respect to complete skin clearance1 PASI 100 responses* in patients who entered the BE RADIANT OLE 100 Proprietary and Confidential Prope
Slide 7: Consecutive positive Phase 3 studies in IL-17 mediated diseases
Bimekizumab has delivered 8 consecutive positive Phase 3 studies to-date in IL-17 mediated diseases Psoriasis BE VIVID (PS0009) NCT03370133 (vs ustekinumab*) Psoriatic Arthritis BE READY (PS0013) BE OPTIMAL (PA0010) Proprietary and Confidential Property of UCB NCT03410992 (vs placebo) NCT03895203 (v
Slide 8: Introduction to Bimekizumab Phase 3 Studies in axSpA and PsA
Introduction to Bimekizumab Phase 3 Proprietary and Confidential Property of UCB Dr. John Ioannou Studies in axSpA and PsA BMedSci, MB BS, PhD, FRCP Head of Medical Affairs, Rheumatology, UCB Content aligned to information publicly available in abstracts Bimekizumab is not approved for use in nr-axS
Slide 9: axSpA and PsA have many overlapping clinical features
axSpA and PsA have many overlapping clinical features1,2 Uveitis Psoriasis axSpA3,4 PsA5 axSpA6 PsA15 Treatment goals and reality 16–40% 7–18% 13% 94% Guidelines recommend treatment should be aimed at reaching the Proprietary and Confidential Property of UCB IBD Sacroiliitis target of remission, or
Slide 10: Phase 3 clinical development program in axSpA and PsA
The Phase 3 clinical development program in axSpA and PsA is aimed at elevating standards of care Phase 3 BE MOBILE 11 BE MOBILE 22 studies Phase 3 double-blind study in patients with Phase 3 double-blind study in patients with active non-radiographic axSpA (nr-axSpA) active ankylosing spondylitis (
Slide 11: Bimekizumab in Active Ankylosing Spondylitis: BE MOBILE 2
Bimekizumab in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from BE MOBILE 2, a Phase 3, Multicentre, Randomised, Placebo-Controlled Study Désirée van der Heijde,1 Xenofon Baraliakos,2 Maxime Dougados,3 Matthew Brown,4 Denis Poddubnyy,5 Filip Van den Bosch,6 Nigil Haroon,7
Slide 12: Study Design
Study Design Key ✔ ≥18 years of age with AS meeting mNY criteria inclusion ✔ Active disease at screening and baseline (BASDAI ≥4 and spinal pain ≥4) criteria ✔ Failure to respond to two different NSAIDs, or history of intolerance or contraindication to NSAIDs Key Failure of >1 TNFi and any previous
Slide 13: Patient Demographics and Baseline Disease Characteristics
Patient Demographics and Baseline Disease Characteristics PBO BKZ 160 mg Q4W n=111 n=221 Age, years, mean (SD) 39.2 (12.6) 41.0 (12.1) Sex, male, n (%) 80 (72.1%) 160 (72.4%) HLA-B27 positive, n (%) 93 (83.8%) 191 (86.4%) Symptom duration, years, mean (SD) 11.9 (8.6) 14.2 (11.0) ASDAS-CRP, mean (SD)
Slide 14: Significantly Greater ASAS40 Response Rate with BKZ vs PBO
Significantly Greater ASAS40 Response Rate with BKZ vs PBO Primary endpoint: ASAS40 response with BKZ compared to PBO at Week 16 ASAS40 response at Week 16 (NRI) ASAS40 kinetics of response to Week 24 (NRI) 100 100 Double-blind period Maintenance period PBO/BKZ 160 mg Q4W; n=111 80 80 BKZ 160 mg Q4W
Slide 15: Primary and All Ranked Secondary Endpoints Were Met at Week 16
Primary and All Ranked Secondary Endpoints Were Met at Week 16 BKZ PBO 160 mg Odds ratio Least squares mean difference Efficacy endpoint p valuea n=111 Q4W vs PBO (95% CI) vs PBO (95% CI) n=221 1 ASAS40,* n (%) 25 (22.5) 99 (44.8) <0.001 2 ASAS40 (TNFi-naϊve patients),† n (%) 22 (23.4)b 84 (45.7)c <
Slide 16: Consistent ASAS40 Response in TNFi-Naïve and TNFi-Experienced Patients
Consistent ASAS40 Response Rate with BKZ in TNFi-Naïve and TNFi-Experienced Patients Ranked secondary endpoint: ASAS40 response at Week 16 in TNFi-naïve patients Exploratory endpoint: ASAS40 response at Week 16 in TNFi-experienced patients Overall population (NRI) TNFi-naïve patients (NRI) TNFi-expe
Slide 17: Improvement in ASDAS with BKZ
Improvement in ASDAS with BKZ Exploratory endpoints: ASDAS disease states and change from baseline in ASDAS-CRP with BKZ compared to PBO ASDAS-CRP CfB (MI) ASDAS Disease States (OC) Weeks 0 4 8 12 16 20 24 PBO BKZ PBO BKZ PBO → BKZ BKZ 0.0 100 2.7 6.8 3.6 Double-blind period Maintenance period 6.3 1
Slide 18: Reduction in Objective Signs of Inflammation with BKZ
Reduction in Objective Signs of Inflammation with BKZ Exploratory endpoints: Change from baseline in MRI spine Berlin score and SPARCC MRI SIJ score, and median hs-CRP with BKZ compared to PBO MRI spine Berlin score SPARCC MRI SIJ score hs-CRP to Week 24 (MI) CfB at Week 16 (OC)a,b CfB at Week 16 (O
Slide 19: Safety Overview
Safety Overview Double-blind period Overall (Weeks 0–16) (Weeks 0–24) PBO BKZ 160 mg Q4W BKZ 160 mg Q4W Totala n (%) n=111 n=221 N=330 Any treatment-emergent adverse event (TEAE) 48 (43.2) 120 (54.3) 183 (55.5) Most frequently reported TEAEsb Nasopharyngitis 4 (3.6) 17 (7.7) 21 (6.4) Diarrhoea 1 (0.
Slide 20: Conclusions
Conclusions The BE MOBILE 2 phase 3 study, evaluating dual inhibition of IL-17A and IL-17F with bimekizumab in patients with AS, met all its primary and secondary endpoints. Patients with active AS treated with bimekizumab showed rapid and clinically meaningful reductions in key signs and symptoms o
Slide 21: Bimekizumab in Active Non-Radiographic axSpA: BE MOBILE 1
Presentation POS0939 Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from Proprietary and Confidential Property of UCB BE MOBILE 1, a Phase 3, Multicentre, Randomised, Placebo Controlled Study A. Deodhar, D. van der Heijde, LS. Gensler, H. Xu,
Slide 22: Study design
Study design Proprietary and Confidential Property of UCB Enrolled patients were eligible to receive non-biologic rescue therapy from Week 20, at the discretion of the investigator, while continuing to receive BKZ. [a] Patients who are MRI negative must have elevated CRP and be HLA-B27 positive at s
Slide 23: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics BKZ 160 mg PBO Q4W n=126 n=128 Age, years, mean (SD) 39.4 (11.8) 39.5 (11.1) Sex, male, n (%) 65 (51.6%) 73 (57.0%) HLA-B27 positive, n (%) 94 (74.6%) 103 (80.5%) Proprietary and Confidential Property of UCB Symptom duration, years, mean (SD) 9.0 (9.
Slide 24: Primary and All Ranked Secondary Endpoints were Met at Week 16
Primary and All Ranked Secondary Endpoints were Met at Week 16a ASAS40 to Week 24 (NRI) Response rates at Week 16 for Change from baseline in continuous binary endpoints (NRI) endpoints at Week 16 (RBMI) Proprietary and Confidential Property of UCB Randomised set. Missing data were imputed using non
Slide 25: Reductions of MRI SIJ Inflammation and hs-CRP with BKZ vs Placebo
Substantial Reductions of MRI SIJ Inflammation by Week 16 and hs-CRP by Week 2 were Achieved with BKZ vs. Placeboa Change from baseline in SPARCC MRI SIJ score Change in median hs-CRP at Week 16 (OC) Weeks 0–24 (MI) Proprietary and Confidential Property of UCB Randomised set. MRI data are reported a
Slide 26: At Week 24, >50% of Patients Initially Randomized to BKZ Achieved ASDAS<2.1
At Week 24, >50% of Patients Initially Randomized to BKZ had Achieved ASDAS<2.1 Proprietary and Confidential Property of UCB Randomised set. Data reported as observed case. [a] At Week 16, patients on PBO switched to BKZ. VHD: ASDAS >3.5; HD: ASDAS ≥2.1–≤3.5; LD: ASDAS ≥1.3–<2.1; ID: ASDAS <1.3. ASD
Slide 27: Consistency of BKZ Across the Spectrum of Axial Spondyloarthritis
Consistency of BKZ Across the Spectrum of Axial Spondyloarthritis Results from the BE MOBILE 2 study in patients with AS (i.e. radiographic axial spondyloarthritis) were consistent with findings from the BE MOBILE 1 study in patients with non-radiographic axial spondyloarthritis (nr-axSpA).1 Patient
Slide 28: Safety Overview
Safety Overview Double-blind period Overall (Weeks 0 - 16) (Weeks 0 - 24) PBO BKZ 160 mg Q4W BKZ 160 mg Q4W Totala n (%) n=126 n=128 N=244 Any TEAE 71 (56.3) 80 (62.5) 124 (50.8) Most frequently reported TEAEs (>3%) by preferred term Proprietary and Confidential Property of UCB Upper respiratory tra
Slide 29: Summary
Summary Disease activity Objective signs ASDAS, BASDAI, of inflammation ASDAS-MI, ASDAS <2.1 SPARCC MRI SIJ score, hs-CRP In patients with active nr- axSpA, subcutaneous BKZ Proprietary and Confidential Property of UCB 160 mg Q4W achieved the primary and all ranked Signs and symptoms Quality of life
Slide 30: Bimekizumab in bDMARD-Naïve Patients with PsA: BE OPTIMAL
Bimekizumab in bDMARD-Naïve Patients with Psoriatic Arthritis: 24-Week Efficacy & Safety from BE OPTIMAL, a Phase 3, Multicentre, Randomised, Placebo-Controlled, Active Reference Study Iain B. McInnes,1 Laura C. Coates,2 Robert Landewé,3 Philip J. Mease,4 Christopher T. Ritchlin,5 Yoshiya Tanaka,6 A
Slide 31: Study Design
Study Design ✔ ≥18 years of age with adult-onset PsA fulfilling CASPAR criteria with a duration of ≥6 months Key inclusion ✔ TJC ≥3/68 and SJC ≥3/66 criteria ✔ ≥1 active psoriatic lesions and/or a documented history of PSO Key exclusion Current or prior exposure to any biologics for treatment of PsA
Slide 32: Primary, Secondary and Other Endpoints
Primary, Secondary and Other Endpoints Primary endpoint • ACR50 response at Week 16 Ranked secondary endpoints • HAQ-DI CfB at Week 16 • PASI90 response at Week 16 • SF-36 PCS CfB at Week 16 • MDA response at Week 16 • vdHmTSS CfB at Week 16 in patients with hs-CRP ≥6 mg/L and/or ≥1 bone erosion at
Slide 33: Patient Demographics and Baseline Disease Characteristics
Patient Demographics and Baseline Disease Characteristics Reference Arm Placebo BKZ 160 mg Q4W (ADA 40 mg Q2W) n=281 n=431 n=140 Age, years, mean (SD) 48.7 (11.7) 48.5 (12.6) 49.0 (12.8) Sex, male, n (%) 127 (45.2) 201 (46.6) 71 (50.7) BMI, kg/m2, mean (SD) 29.6 (6.1) 29.2 (6.8) 28.4 (5.9) PsA durat
Slide 34: BE OPTIMAL Met Primary and All Ranked Secondary Endpoints
BE OPTIMAL Met Primary and All Ranked Secondary Endpoints (Week 16) Statistically Least squares mean differenceb BKZ vs Efficacy endpoint p valuea Odds ratiob BKZ vs placebo (95% CI) significant placebo (95% CI) 1 ACR50 (NRI) <0.001 Yes 7.1 (4.6, 11.0) – HAQ-DI Change from Baseline 2 <0.001 Yes – −0
Slide 35: Efficacy: ACR50 and PASI90 Responses at Week 16
Efficacy: ACR50 and PASI90 Responses at Week 16 (NRI) BKZ demonstrated superiority vs placebo in improvements in joint and skin outcomes at Week 16 Primary Endpoint: ACR50 PASI90a 100 100 Δ = 58.4% 80 80 p<0.001 Δ = 33.9% Patients (%) Patients (%) p<0.001 61.3% 60 60 45.7% 43.9% 41.2% 40 40 20 20 10
Slide 36: Efficacy: ACR Response Criteria to Week 24
Efficacy: ACR Response Criteria to Week 24 (NRI) BKZ demonstrated improvements vs placebo in achievement of ACR response criteria at Week 16 ACR20 ACR50 ACR70 Active Active Active Double-blind treatment-blind Double-blind treatment-blind Double-blind treatment-blind 100 period period 100 period peri
Slide 37: Efficacy: Psoriasis Area and Severity Index to Week 24
Efficacy: Psoriasis Area and Severity Index to Week 24 (NRI) Over half of BKZ patients achieved complete skin clearance by Week 24 PASI75 PASI90 PASI100 Active Active Active Double-blind treatment-blind Double-blind treatment-blind Double-blind treatment-blind 100 period period 100 period period 100
Slide 38: Efficacy: Proportion of Patients Achieving MDA
Efficacy: Proportion of Patients Achieving MDA to Week 24 (NRI) BKZ demonstrated superiority vs placebo in achievement of MDA response (composite index) at Week 16 100 Double-blind period Active treatment-blind period MDA response defined as achievement 80 of at least 5 of the 7 following criteria:
Slide 39: Efficacy: Radiographic Outcomes at Week 16
Efficacy: Radiographic Outcomes at Week 16 (MI) BKZ demonstrated superiority vs placebo in inhibition of structural progression at Week 16 Overall Population At-Risk Population (Radiographic Set) (hs-CRP ≥6 mg/L and/or ≥1 Bone Erosion at Baseline) 0.5 0.5 0.36 vdHmTSS score change from baseline 0.31
Slide 40: Safety: Overall
Safety: Overall Week 0–16 Week 0–24 Reference Arm Reference Arm Placebo BKZ 160 mg Q4W BKZ 160 mg Q4W Total n (%) (ADA 40 mg Q2W) (ADA 40 mg Q2W) n=281 n=431 n=702a n=140 n=140 Any TEAE 139 (49.5) 258 (59.9) 83 (59.3) 395 (56.3) 96 (68.6) Serious TEAEs 3 (1.1) 7 (1.6) 2 (1.4) 20 (2.8) 5 (3.6) Discon
Slide 41: Conclusions
Conclusions The BE OPTIMAL phase 3 study, evaluating dual inhibition of IL-17A and IL-17F with bimekizumab in bDMARD-naïve patients with PsA, met all its primary and secondary endpoints. Bimekizumab-treated bDMARD-naïve patients with PsA showed improvements in joint and skin outcomes, as well as in
Slide 42: Bimekizumab in Active PsA with Inadequate Response to TNFi: BE COMPLETE
Bimekizumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from BE COMPLETE, a Phase 3, Multicentre, Randomised, Placebo-Controlled Study Joseph F. Merola,1 Iain B. McInnes,2 Christopher Ritchlin,3 Philip J. Me
Slide 43: Disclosures & Acknowledgements
Disclosures & Acknowledgements Disclosures JFM: Consultant and/or investigator for AbbVie, Amgen, Bayer, Biogen, BMS, Celgene, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi-Regeneron Sun Pharma, and UCB Pharma. IBM: Consulting fees and honoraria from AbbVie, BMS, Boehringer Ing
Slide 44: Study Design
Study Design ✔ Adult-onset PsA fulfilling CASPAR criteria with a duration of ≥6 months Key inclusion ✔ TJC ≥3/68 and SJC ≥3/66 criteria ✔ ≥1 active psoriatic lesions and/or a documented history of PSO ✔ Inadequate response or intolerance to 1 or 2 TNFi for either PsA or PSO Key exclusion Current or
Slide 45: Primary, Secondary and Other Endpoints
Primary, Secondary and Other Endpoints Primary endpoint • ACR50 response at Week 16 Ranked secondary endpoints • HAQ-DI CfB at Week 16 • PASI90 response at Week 16 • SF-36 PCS CfB at Week 16 • MDA response at Week 16 Secondary and other efficacy endpoints • ACR20 and ACR70 response at Week 16 • PASI
Slide 46: Patient Demographics and Baseline Disease Characteristics
Patient Demographics and Baseline Disease Characteristics Placebo BKZ 160 mg Q4W n=133 n=267 Age, years, mean (SD) 51.3 (12.9) 50.1 (12.4) Sex, male, n (%) 60 (45.1) 130 (48.7) BMI, kg/m2, mean (SD) 29.0 (5.4) 30.1 (6.5) PsA duration,a years, mean (SD) 9.2 (8.1) 9.6 (9.9) Concomitant methotrexate, n
Slide 47: BE COMPLETE Met Primary and All Ranked Secondary Endpoints
BE COMPLETE Met Primary and All Ranked Secondary Endpoints (Week 16) Statistically Least squares mean difference BKZ vs Efficacy endpoint p valuea Odds ratioa BKZ vs placebo (95% CI)b significant placebo (95% CI)b 1 ACR50 (NRI) <0.001 Yes 11.1 (5.4, 22.9) – 2 HAQ-DI CfB (RBMI) <0.001 Yes – –0.3 (–0.
Slide 48: Efficacy: ACR50 and PASI90 Responses at Week 16
Efficacy: ACR50 and PASI90 Responses at Week 16 (NRI) BKZ demonstrated superiority vs placebo in improvements in joint and skin outcomes at Week 16 Primary Endpoint: ACR50 PASI90a 100 100 Δ = 62.0% p<0.001 80 80 Δ = 36.6% 68.8% p<0.001 60 60 Patients (%) Patients (%) 43.4% 40 40 20 20 6.8% 6.8% 0 0
Slide 49: Efficacy: ACR Response Criteria to Week 16
Efficacy: ACR Response Criteria to Week 16 (NRI) BKZ demonstrated improvements vs placebo in achievement of all ACR response criteria at Week 16 ACR20 ACR50 ACR70 100 100 100 Nominal p<0.001 at Week 16 80 80 80 67.0% p<0.001 at Week 16 Patients (%) Patients (%) Patients (%) 60 60 60 43.4% Nominal p<
Slide 50: Efficacy: Psoriasis Area and Severity Index to Week 16
Efficacy: Psoriasis Area and Severity Index to Week 16 (NRI) Over half of BKZ patients achieved complete skin clearance at Week 16 PASI75 PASI90 PASI100 100 100 100 p<0.001 82.4% at Week 16 80 80 80 Nominal p<0.001 68.8% at Week 16 Nominal p<0.001 58.5% Patients (%) Patients (%) Patients (%) 60 at W
Slide 51: Efficacy: Proportion of Patients Achieving MDA
Efficacy: Proportion of Patients Achieving MDA to Week 16 (NRI) BKZ demonstrated superiority vs placebo in achievement of MDA response (composite index) at Week 16 100 MDA response defined as achievement 80 of at least 5 of the 7 following criteria: p<0.001 • Tender joint count ≤1 at Week 16 Patient
Slide 52: Efficacy: Physical Functioning to Week 16
Efficacy: Physical Functioning to Week 16 (MI) BKZ demonstrated superiority vs placebo in improvements in physical functioning at Week 16 HAQ-DI CfB SF-36 PCS CfB Weeks 9 0 4 8 12 16 8 Change from baseline (mean [SE]) 0.0 7.3 7 Change from baseline (mean [SE]) -0.07 -0.1 6 Improvement 5 Improvement
Slide 53: Efficacy: TJC and SJC CfB at Week 16
Efficacy: TJC and SJC CfB at Week 16 (MI) BKZ demonstrated numerically greater reduction of tender and swollen joints at Week 16 TJC SJC 0 0 Change from baseline at Week 16 Change from baseline at Week 16 -2.4 -2 -5 -2.0 (mean [SE]) (mean [SE]) -4 -10 -6 -10.9 -15 -8 -7.0 BL TJC, mean (SD) BL SJC, m
Slide 54: Safety: Overall
Safety: Overall Placebo BKZ 160 mg Q4W n (%) n=132a n=267 Any TEAE 44 (33.3) 107 (40.1) Serious TEAEs 0 5 (1.9) Discontinuation due to TEAEs 0 2 (0.7) Drug-related TEAEs 4 (3.0) 35 (13.1) Severe TEAEs 0 5 (1.9) Deaths 0 0 Most frequently reported TEAEs on the BKZ arm Nasopharyngitis 1 (0.8) 10 (3.7)
Slide 55: BE COMPLETE Conclusions
BE COMPLETE Conclusions The BE COMPLETE phase 3 study, evaluating dual inhibition of IL-17A and IL-17F with bimekizumab in patients with PsA with inadequate response or intolerance to TNFi, met all its primary and secondary endpoints. • Bimekizumab-treated patients with PsA and inadequate response o
Slide 56: Consistency of BKZ Across Psoriatic Arthritis Patient Populations
Consistency of BKZ Across Psoriatic Arthritis Patient Populations BE OPTIMAL (bDMARD-naïve patients) BE COMPLETE (TNF-IR patients) ACR50 at Week 16 (NRI) ACR50 at Week 16 (NRI) 100 Δ = 33.9% Δ = 36.6% 100 p<0.001 p<0.001 80 Patients (%) 80 Patients (%) 60 60 43.9% 43.4% 40 40 20 10.0% 20 6.8% 0 0 Pl
Slide 57: Q&A
Lianne S. Gensler, M.D. Professor of Medicine, Director, Spondyloarthritis Research Program & Clinic, University of California, San Francisco, U.S Proprietary and Confidential Property of UCB Dr. Joseph Merola Q&A Brigham and Women’s Hospital, Harvard Medical School, Boston, U.S. Emmanuel Caeymaex E
Slide 58: Thank you
Proprietary and Confidential Property of UCB Thank you GL-N-BK-AS-2200005 Date of preparation: May 2022 62
Slide 59: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB GL-N-BK-AS-2200005 Date of preparation: May 2022